A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis.

Nicholas O OpokuFelix DoeBettina DubbenNicole FetchoKerstin FischerPeter U FischerShelter GordorCharles W GossMichael E GyasiAchim HoeraufAugustine R HongEric KanzaChristopher L KingRuth LaryeaDaphne LewMahmood A SeiduGary J Weil

Published in: PLoS neglected tropical diseases (2023)

The study is registered at Cinicaltrials.gov under the number NCT04188301.

Keyphrases

open label
clinical trial
physical activity
squamous cell carcinoma
study protocol
rectal cancer
combination therapy
placebo controlled